Details for Patent: 7,119,106
✉ Email this page to a colleague
Summary for Patent: 7,119,106
Title: | Pharmaceutical compositions of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline |
Abstract: | Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines reduce the levels of TNF.alpha. in a mammal. Typical embodiments are 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7-tetrafuoroisoindoline and 1,3-dioxo-2-(2,6-dioxo-3 -methylpiperidin-3-yl)-4-aminoisoindoline. |
Inventor(s): | Muller; George W. (Bridgewater, NJ), Stirling; David I. (Branchburg, NJ), Chen; Roger Shen-Chu (Edison, NJ) |
Assignee: | Celgene Corporation (Summit, NJ) |
Application Number: | 10/337,602 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,119,106 |
Patent Claim Types: see list of patent claims | Composition; Compound; Dosage form; Formulation; | More… ↓ |
Drugs Protected by US Patent 7,119,106
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,119,106
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
European Patent Office | 0925294 | ⤷ Subscribe | 91359 | Luxembourg | ⤷ Subscribe |
European Patent Office | 0925294 | ⤷ Subscribe | CA 2007 00054 | Denmark | ⤷ Subscribe |
European Patent Office | 0925294 | ⤷ Subscribe | 07C0056 | France | ⤷ Subscribe |
European Patent Office | 0925294 | ⤷ Subscribe | SPC033/2007 | Ireland | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |